Penumbra, Inc.
Rank #88Op. LeveragePEN · NYSE · Healthcare
Penumbra, Inc. (PEN) — Rank #88 by gross profitability (GP/assets 0.48) · ROE 11.6% · Piotroski F-Score 6 / 9.
As-of 2026-09-15 · CIK 0001321732 · all metrics point-in-time as of the filing date.
About
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally.
Show moreShow less
It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors.
The company was incorporated in 2004 and is based in Alameda, California.
- Industry
- Medical Devices
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- December 31
- Website
- penumbrainc.com
Financials
Stable
Direction over 5 fiscal years
- Free cash flowimproving
- Gross marginstable
- Gross profitabilityimproving
- Net cashimproving
- Operating marginimproving
- Return on equityimproving
- Share count (dilution)improving
Red flags: fcf_ni_divergence_unfavorable — rating capped at Stable
Monitoring diagnostic of business direction — not a prediction of returns.
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-31filed 2026-02-25 | 2024-12-31filed 2025-02-18 | 2023-12-31filed 2024-02-22 | 2022-12-31filed 2023-02-23 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 1,403.7 | 1,194.6 | 1,058.5 | 847.1 |
| Revenue growth (YoY) | 17.5% | 12.9% | 25.0% | 13.3% |
| Gross profit | 942.4 | 755.0 | 682.6 | 535.2 |
| Gross margin | 67.1% | 63.2% | 64.5% | 63.2% |
| Net income | 177.7 | 14.0 | 91.0 | (2.0) |
| Net margin | 12.7% | 1.2% | 8.6% | -0.2% |
| EPS (diluted) | $4.52 | $0.36 | $2.32 | -$0.05 |
| EPS growth (YoY) | 1155.6% | -84.5% | 4740.0% | — |
| Cash flow | ||||
| Operating cash flow | 238.7 | 168.5 | 97.3 | (55.7) |
| Capital expenditures | 63.7 | 21.2 | 15.2 | 19.3 |
| Free cash flow | 174.9 | 147.3 | 82.1 | (75.0) |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?